25 completed, 12 unknown, 6 terminated, 3 withdrawn. 14 Not applicable, 13 Phase 2, 9 Phase 3, 8 Phase 1, 7 Phase 4.
Follow Intravitreal Injections: new trials by email Literature Review of Intravitreal Injections trials Research Report on Intravitreal Injections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection - Neovascular Age-related Macular Degeneration (nAMD) | Phase 3 | Not yet recruiting | Rophibio, Inc. | 434 | 2025-07-01 | 2025-04-06 |
| Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration Faricimab Injection [Vabysmo] - Neovascular Age-Related Macular Degeneration (nAMD), Treatment-naïve | Completed | Copenhagen University Hospital, Rigshospitalet | 742 | 2024-11-15 | 2026-03-27 | |
| Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy Faricimab Injection [Vabysmo] - Intraocular Inflammation | Completed | Copenhagen University Hospital, Rigshospitalet | 6053 | 2024-11-10 | 2025-03-30 | |
| Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO] - Diabetic Macular Edema | Phase 4 | Unknown | Vista Klinik | 30 | 2022-11-01 | 2022-11-09 |
| Intravitreal Sirolimus as Therapeutic Approach to Uveitis Intravitreal injection 440mcg, Intravitreal injection of sirolimus 880mcg - Uveitis, Intermediate Uveitis | Phase 2 | Withdrawn | Stanford University | 2022-09-01 | 2023-10-26 | |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa RNA antisense oligonucleotide for intravitreal injection - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 | Terminated | Laboratoires Thea | 21 | 2021-09-16 | 2024-08-07 |
| Brolucizumab for CNV Associated With Pathologic Myopia Intravitreal injection - Pathologic Myopia | Not applicable | Unknown | The Filatov Institute of Eye Diseases and Tissue Therapy | 50 | 2021-04-01 | 2022-03-24 |
| BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration intravitreal injection - Macula Lutea Degeneration | Not applicable | Unknown | Benha University | 40 | 2020-08-05 | 2021-05-12 |
| Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept Brolucizumab 6 mg solution for intravitreal injection - Neovascular Age-related Macular Degeneration | Phase 4 | Terminated | Vista Klinik | 16 | 2020-07-20 | 2021-12-29 |
| A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment ONL1204, Intravitreal Injection, Collection of ocular fluids - Rhegmatogenous Retinal Detachment - Macula Off | Phase 1 | Completed | ONL Therapeutics | 14 | 2019-10-21 | 2024-09-24 |
| Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema Intravitreal injection (4mg/0.1ml), Superachoroidal injection (4 mg/0.1ml), Suprachoroidal injection (2mg/0.1ml) - Safety, Efficacy | Not applicable | Unknown | Azza Mohamed Ahmed Said | 45 | 2019-03-13 | 2019-09-03 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME PPV/MP, Intravitreal injection - Diabetic Retinopathy, Macular Edema | Phase 3 | Completed | Rush Eye Associates | 11 | 2018-09-04 | 2021-12-02 |
| Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT Intracameral injection, Intravitreal injection - Glaucoma, Neovascular, Vascular Endothelial Growth Factor Overexpression | Not applicable | Recruiting | Prince of Songkla University | 40 | 2018-08-01 | 2025-08-21 |
| Antiangiogenic Therapy of CNV Associated With Angioid Streaks Intravitreal injection - Angioid Streaks of Macula | Not applicable | Unknown | The Filatov Institute of Eye Diseases and Tissue Therapy | 100 | 2018-03-27 | 2021-02-03 |
| Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Myopia Intravitreal injection - Pathologic Myopia | Not applicable | Completed | The Filatov Institute of Eye Diseases and Tissue Therapy | 122 | 2018-03-27 | 2023-01-25 |
| Antiangiogenic Therapy of Choroidal Neovascularisation Associated With Central Chorioretinitis Intravitreal injection, Fluorescent angiography, Visometry - Chorioretinitis | Not applicable | Unknown | The Filatov Institute of Eye Diseases and Tissue Therapy | 100 | 2018-03-27 | 2021-02-03 |
| VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP Bevacizumab Injection, Ranibizumab Ophthalmic - Retinopathy of Prematurity Both Eyes, Retinal Disease | Phase 4 | Completed | Universidad Autonoma de San Luis Potosí | 16 | 2017-05-23 | 2019-01-09 |
Showing 20 of 48. Sign in to see all of them.
Choroidal Neovascularization (7) · Eye Diseases (6) · Macular Edema (6) · Retinal Diseases (5) · Retinitis Pigmentosa (4) · Usher Syndromes (4) · Vision Disorders (4) · Diabetic Retinopathy (3) · Eye Abnormalities (3) · Eye Diseases, Hereditary (3) · Macular Degeneration (3) · Retinal Detachment (3) · Uveitis (3) · Angioid Streaks (2) · Glaucoma, Neovascular (2)
Hallym University Medical Center (4) · Merck Sharp & Dohme LLC (4) · The Filatov Institute of Eye Diseases and Tissue Therapy (4) · Laboratoires Thea (3) · Vista Klinik (3) · Asociación para Evitar la Ceguera en México (2) · Copenhagen University Hospital, Rigshospitalet (2) · Prince of Songkla University (2) · Allegro Ophthalmics, LLC (1) · Azza Mohamed Ahmed Said (1) · Benha University (1) · Heidelberg University (1) · Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA (1) · Instituto de Olhos de Goiania (1) · Minia University (1)
United States (11) · Mexico (4) · Ukraine (4) · France (3) · Germany (3) · South Korea (3) · Brazil (2) · Canada (2) · Denmark (2) · Switzerland (2) · Thailand (2) · United Kingdom (2) · Australia (1) · China (1) · Egypt (1)
Amy Schaberg, BSN (4) · Andrii MD Korol, PhD (4) · Abdelrahman G Salman, MD (1) · Assoc.Prof.Weerawat Kiddee, MD (1) · Asst.Prof.Weerawat Kiddee, MD (1) · Christian Pruente, MD (1) · Dennis M Marcus, MD (1) · Griselda Alvarez, Fellow (1) · Jiwon Lim, MDPhD (1) · Jost Jonas, PhD MD (1)
PMID 25966740, PMID 27604764, PMID 27836430, PMID 28084038, PMID 29729809, PMID 30175123, PMID 31215818, PMID 31267688, PMID 32303499, PMID 33292788, PMID 33600134, PMID 34188440, PMID 35083234, PMID 36890535, PMID 37172782, PMID 37418643, PMID 42105126, PMID 42141825
2014 (1), 2018 (1)